CanAssist Breast is a prognostic test developed by OncoStem that classifies the patients as ‘low-risk’ or ‘high-risk’ based on the patient’s risk of breast cancer recurrence over five years. CanAssist Breast provides information about the risk of recurrence of early-stage, hormone receptor-positive breast cancer patients. This test analyses critical biomarkers in the tumour to assess the risk of recurrence, and helps oncologists to personalize treatment plans.
Recurrence risk prediction is an important step towards personalized cancer treatment. In up to 3 out of 4 early-stage hormone receptor-positive breast cancer patients, the benefit from chemotherapy is not outweighed by its risks.
With vital insights gained through the results of CanAssist Breast, it is possible to identify the patient's risk of a cancer recurrence over five years. By understanding the tumour biology, the test calculates the risk of recurrence and classifies the patients as ‘low risk’ and ‘high risk’ using a machine learning statistical algorithm. This enables the doctors to personalize treatment for each individual, resulting in improved quality of life and better clinical outcomes.
CanAssist Breast can precisely identify the need for chemotherapy among early-
stage breast cancer patients, by assessing their risk of recurrence.
Chemotherapy takes a toll on both physical and mental health of patients undergoing
treatment. It is primarily designed to target the fast-growing cancer cells. However, it
also destroys healthy cells in its course, causing further debilitating side effects in the
patients.
CanAssist Breast determines the patient’s risk of breast cancer
recurrence over five years, classifying patients as ‘low-risk’ or
‘high-risk’ for cancer recurrence.The 'low-risk' patients’ can
possibly avoid chemotherapy and its side effects and
personalize their cancer treatment.
Cancer cells multiply fast and chemotherapy-drugs are designed to kill these fast-growing cells. Unfortunately, these drugs pass through the entire body and kill all fast-growing cells including the healthy ones. This affects the internal functioning of the body, leading to further complications. Some of the significant side effects of chemotherapy include:
The patients must meet the following criteria to take the CanAssist Breast test:
If you meet the eligibility criteria, your doctor can prescribe CanAssist Breast
post-surgery. Supported with the test results, your doctor can decide on how
likely it is that you would benefit from addition of chemotherapy to your
treatment plan.
*The test is not applicable for patients diagnosed with DCIS (Ductal Carcinoma In- Situ).
